EXTRAPULMONARY NEUROENDOCRINE CARCINOMA
Clinical trials for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new EXTRAPULMONARY NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for EXTRAPULMONARY NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets rare, aggressive cancer in early trial
Disease control OngoingThis early-phase trial tests a new drug called BI 764532 (Obrixtamig) given together with standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC), a rare and fast-growing cancer. The study involves about 55 adults whose tumors have a specific marker (DLL3). …
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo aimed at tough cancers pulled before starting
Disease control TerminatedThis study planned to test a combination of two drugs—tarlatamab and sacituzumab govitecan—in adults with extensive-stage small cell lung cancer or extrapulmonary neuroendocrine cancer that had returned or not responded to prior treatment. The goal was to find a safe dose and see…
Matched conditions: EXTRAPULMONARY NEUROENDOCRINE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC